[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Petersenn et al., 2014 - Google Patents

Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Petersenn et al., 2014

View HTML
Document ID
5355297667629240393
Author
Petersenn S
Farrall A
Block C
Melmed S
Schopohl J
Caron P
Cuneo R
Kleinberg D
Colao A
Ruffin M
Hermosillo Reséndiz K
Hughes G
Hu K
Barkan A
Publication year
Publication venue
Pituitary

External Links

Snippet

Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term efficacy and safety of …
Continue reading at link.springer.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Similar Documents

Publication Publication Date Title
Petersenn et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study
Sheppard et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, phase III study
Petersenn et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial
Colao et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study
Neggers et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly
Rosario et al. The brain–to–pancreatic islet neuronal map reveals differential glucose regulation from distinct hypothalamic regions
Pieroni et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function
Ricci et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors
Schmid et al. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors
Bronstein et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
Lo et al. Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice
Huang et al. Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism
Samson et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Chanson et al. Control of IGF‐I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Jassam et al. Analytical and clinical challenges in a patient with concurrent type 1 diabetes, subcutaneous insulin resistance and insulin autoimmune syndrome
Fleseriu et al. Safety and tolerability of pasireotide long-acting release in acromegaly—results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
Jessen et al. Central nervous system GLP-1 receptors regulate islet hormone secretion and glucose homeostasis in male rats
Petersenn et al. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study
Neggers et al. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Parvanova et al. Blood pressure and metabolic effects of acetyl-l-carnitine in type 2 diabetes: DIABASI randomized controlled trial
Roustit et al. Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle
Petersenn et al. Pasireotide (SOM230), a novel multireceptor‐targeted somatostatin analogue, is well tolerated when administered as a continuous 7‐day subcutaneous infusion in healthy male volunteers
Baretić Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic?
Su et al. Hyperinsulinemic hypoglycemia associated with insulin antibodies caused by exogenous insulin analog
Cuvelier et al. Overexpression of wild-type human alpha-synuclein causes metabolism abnormalities in Thy1-aSYN transgenic mice